Fox Chase Cancer Center News

PHILADELPHIA (June 27, 2023)—Fox Chase Cancer Center is proud to announce that Sanjay S. Reddy, MD, FACS, has been appointed to the Marvin S. Greenberg, MD, Chair in Pancreatic Cancer Surgery.

PHILADELPHIA (June 26, 2023) — Integrins are a type of protein found on the surface of all cells that helps them communicate with and attach to nearby cells. Under normal circumstances, they play a key role in cell growth and other cellular functions that are beneficial, including cell migration, blood clotting, and immune responses.

PHILADELPHIA (June 21, 2023)—The Pennsylvania Medical Society (PAMED) released its list of the 2023 Top Physicians Under 40 award recipients. Four Fox Chase Cancer Center physicians were honored:

PHILADELPHIA (June 7, 2023)—Jennifer Barsky Reese, PhD, FSBM, an associate professor in the Cancer Prevention and Control research program at Fox Chase Cancer Center, will address the topic of the sexual concerns of cancer survivors on June 13 as part of the National Cancer Institute’s Office of Cancer Survivorship Director’s Series.

PHILADELPHIA (June 6, 2023)—Fox Chase Cancer Center is pleased to announce the hiring of David Loren, MD, FASGE, as professor of medicine and chief of the Section of Gastroenterology in the Department of Medicine.

PHILADELPHIA (June 2, 2023)—Fox Chase Cancer Center and Temple Health researchers will participate in the presentation and discussion of 10 research projects at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 2-6 in Chicago. An asterisk (*) indicates that the author is the main presenter.

PHILADELPHIA (June 2, 2023)—Elizabeth Plimack, MD, MS, Deputy Director and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been appointed Treasurer of the American Society of Clinical Oncology (ASCO).

PHILADELPHIA (June 1, 2023) — Researchers at Fox Chase Cancer Center have utilized banked computed tomography (CT) to evaluate alternate response criteria for early prediction of outcomes in rare pancreatic neuroendocrine tumors (NETs).